<DOC>
	<DOCNO>NCT00544011</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , bevacizumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Drugs use chemotherapy , irinotecan , fluorouracil , capecitabine , work different way stop growth tumor cell , either kill cell stop divide . Giving bevacizumab together combination chemotherapy may kill tumor cell . PURPOSE : This phase II trial study well bevacizumab give together combination chemotherapy work treat patient metastatic colorectal cancer .</brief_summary>
	<brief_title>Bevacizumab Combination Chemotherapy Treating Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Evaluate objective response ( complete partial ) rate patient metastatic colorectal adenocarcinoma treat bevacizumab modify FOLFIRI 3 chemotherapy . Secondary - Determine progression-free overall survival . - Determine tolerance regimen . - Evaluate resectability rate . - Evaluate biological marker predictive efficacy regimen . OUTLINE : This multicenter study . Patients receive bevacizumab IV 30-90 minute day 1 , irinotecan hydrochloride IV 90 minute day 1 3 , fluorouracil IV continuously 46 hour day 1 . Treatment repeat every 2 week 12 course absence disease progression unacceptable toxicity . At 14 day complete chemotherapy , patient progressive stable disease receive maintenance therapy comprise bevacizumab capecitabine . Biological specimen collect baseline fourth course chemotherapy . After completion study therapy , patient follow every 3 month 2 year .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma colon rectum Previously untreated metastatic disease Measurable disease RECIST Must locate prior radiation field No cerebral meningeal metastasis PATIENT CHARACTERISTICS : Inclusion criterion : WHO performance status 01 Life expectancy &gt; 12 week Absolute neutrophil count ≥ 1,000/mm³ Platelet count ≥ 100,000/mm³ Bilirubin ≤ 1.5 time upper limit normal ( ULN ) Transaminases ≤ 2 time ULN ( 5 time ULN liver metastasis present ) Alkaline phosphatase ≤ 2 time ULN ( 5 time ULN liver metastasis present ) Creatinine ≤ 130 μmol/L OR creatinine clearance ≥ 30 mL/min Proteinuria &lt; 2+ urine protein ≤ 1 g/24 hour Not pregnant nursing Fertile patient must use effective contraception Exclusion criterion : Uncontrolled cardiac disease Prior cerebral vascular accident Uncontrolled arterial hypertension Severe renal hepatic insufficiency Prior arteriopathy Bleeding disorder nonhealing wound Coagulopathy Other malignancy within past 2 year except basal cell squamous cell skin cancer curatively treat carcinoma cervix Psychiatric disorder compromise comprehension participation study Intestinal occlusion subocclusion cause medical therapy PRIOR CONCURRENT THERAPY : Inclusion criterion : See Disease Characteristics Exclusion criterion : Prior adjuvant bevacizumab irinotecan hydrochloride Concurrent aspirin ( &gt; 325 mg/day ) therapeutic anticoagulant Surgery past 28 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma rectum</keyword>
</DOC>